Fairmount Funds Management LLC sold $127M of COGT
director at Cogent Biosciences, Inc.. 3,500,000 shares at an average of $36.40, traded Jan 22, 2026, filed Jan 22, 2026.
Score components
- +15RoleDirector
- +25Trade size$127.4M at market
- +10Share of holdings soldSold 39% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -5.5%, 3m -8.6%, 6m +1.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-005924, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 22, 2026 | SOpen-market sale Common Stockindirect: Fairmount Healthcare Fund II LP | -3,500,000 | $36.40 | $127M | 5,503,418 | Jan 22, 2026 |
Related signals
Other insiders at Cogent Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Cogent Biosciences, Inc. | Arlene Morris director | $1.7M 45,510 shares | -100% | |
| 60Notable | COGTsell Cogent Biosciences, Inc. | Fairmount Funds Management LLC director | $243M 7,000,000 shares | -56% | |
| 65Notable | Cogent Biosciences, Inc. | John Edward Robinson Chief Scientific Officer | $3.5M 90,000 shares | -39% | |
| 65Notable | Cogent Biosciences, Inc. | Jessica Sachs Chief Medical Officer | $3.2M 82,642 shares | -38% | |
| 72Notable | Cogent Biosciences, Inc. | John L. Green Chief Financial Officer | $3.0M 77,000 shares | -37% | |
| 65Notable | Cogent Biosciences, Inc. | Evan Kearns Chief Legal Officer | $2.5M 65,000 shares | -37% | |
| 46Moderate | COGTbuy Cogent Biosciences, Inc. | Fairmount Funds Management LLC director | $25M 2,777,777 shares | +45% | |
| 40Moderate | COGTbuy Cogent Biosciences, Inc. | Cole Pinnow Chief Commercial Officer | $332k 43,750 shares | +2085% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.